Home › Companies › CG Oncology, Inc. › 2025-2026

CG Oncology, Inc. 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and CG Oncology, Inc.’s Form 8-K, filed 2026-06-08 (Item 5.07 on EDGAR). Page generated 02 October 2026.

5Reported items
260Asset managers
2,154Fund votes
2026-06-04Meeting date

Proxy season: 2025-2026

Explore CG Oncology, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by CG Oncology, Inc.

These tallies are CG Oncology, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-06-08 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

CG Oncology, Inc. — official shareholder meeting results, meeting held 2026-06-04
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Christina Rossi	67,531,501	--	--	89,825	16,216,685	Majority: yes
Elect Director: Victor Tong, Jr.	62,401,874	--	--	5,219,452	16,216,685	Majority: yes
Proposal 2: Ratification of the Selection of Independent Registered Public Accounting Firm The Company's stockholders ratified the selection by the Audit Committee of the Company's Board of Directors of Ernst & Young LLP as the Company's independent registered	83,711,522	4,103	122,386	--	--	Majority: yes
Proposal 3: Advisory Vote on Executive Compensation The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers as described in the Proxy Statement	65,894,959	1,603,011	123,356	--	16,216,685	Majority: yes

Source: CG Oncology, Inc., Form 8-K, filed with the SEC on 2026-06-08 — read the filing on EDGAR.

How asset managers voted at the CG Oncology, Inc. 2025-2026 meeting

Each item below shows how the 260 asset managers that disclosed a CG Oncology, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of CG Oncology, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. To approve, on an advisory basis, the compensation of the Company's Named Executive Officers.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%

FOR: 65,894,959AGAINST: 1,603,011

CG Oncology, Inc.’s own tally for this item (“Proposal 3: Advisory Vote on Executive Compensation The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers as described in the Proxy Statement”): 65,894,959 for, 1,603,011 against, per its Form 8-K filed 2026-06-08 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 88,007,761 outstanding shares: 75% for, 2% against (77% of the company cast a for/against vote).

The 257 asset managers below cast 99% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the total votes cast at the meeting.

FOR 99%

FOR: 98.5%AGAINST: 1.4%ABSTAIN: 0.0%NOT VOTED: 0.0%

Largest asset managers voting on “To approve, on an advisory basis, the compensation of the Company's Named Executive Officers.” at CG Oncology, Inc., 2025-2026
Asset manager	For	Against	Vote
T. Rowe Price	17,019,290	0	For
Vanguard	9,758,527	3	For
RTW INVESTMENTS, LP	7,010,964	0	For
Decheng Capital LLC	6,371,669	0	For
Fidelity	4,897,136	126	For
Wellington	4,025,019	0	For
BlackRock	3,239,847	7,798	For
Foresite Capital Management VI LLC	2,221,474	0	For
AllianceBernstein	1,497,281	0	For
Avidity Partners Management LP	1,288,948	0	For
State Street	1,271,641	873	For
EcoR1 Capital, LLC	1,272,000	0	For
Polar Capital Holdings Plc	1,257,312	0	For
GEODE CAPITAL MANAGEMENT, LLC	1,172,512	0	For
FRANKLIN ADVISERS INC	1,135,541	0	For
Charles Schwab	1,090,274	0	For
Foresite Capital Management V, LLC	1,004,050	0	For
ORBIMED ADVISORS LLC	948,267	0	For
Jackson National	785,996	0	For
Clearbridge Investments, LLC	727,902	0	For
FRANKLIN STRATEGIC SERIES	727,381	0	For
Putnam	565,781	0	For
Candriam S.C.A.	0	542,036	Against
Ensign Peak Advisors, Inc	456,012	0	For
DRIEHAUS CAPITAL MANAGEMENT LLC	451,352	0	For

Showing the 25 largest of 257 asset managers. See all 257 in the interactive database.

2. To indicate, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of the Company's Named Executive Officers.

SECTION 14A SAY-ON-PAY VOTES

Combines 3 wordings of this item as funds reported it.

99.9% fund support · no official result

ONE YEAR 74%1 YEAR 23%

The 250 asset managers below cast 99.9% of the shares they voted on this item FOR (1,578,514 for, 318 against).

FOR: 1,578,514 (2.1%)AGAINST: 318 (0.0%)ABSTAIN: 22,684 (0.0%)ONE YEAR: 55,076,042 (74.3%)1 YEAR: 16,910,387 (22.8%)3 YEARS: 461,906 (0.6%)THREE YEARS: 59,558 (0.1%)1-YEAR: 42,945 (0.1%)2 YEARS: 2,800 (0.0%)1.0: 103 (0.0%)NOT VOTED: 28 (0.0%)3.0: 1 (0.0%)

Largest asset managers voting on “To indicate, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation o” at CG Oncology, Inc., 2025-2026
Asset manager	For	Vote
T. Rowe Price	0	One Year
Vanguard	0	One Year
RTW INVESTMENTS, LP	0	One Year
Fidelity	0	One Year
Wellington	0	1 Year
BlackRock	0	1 Year
Foresite Capital Management VI LLC	0	1 Year
AllianceBernstein	0	One Year
Avidity Partners Management LP	0	1 Year
State Street	0	One Year
EcoR1 Capital, LLC	1,272,000	For
Polar Capital Holdings Plc	0	One Year
GEODE CAPITAL MANAGEMENT, LLC	0	One Year
FRANKLIN ADVISERS INC	0	One Year
Charles Schwab	0	1 Year
Foresite Capital Management V, LLC	0	1 Year
ORBIMED ADVISORS LLC	0	1 Year
Jackson National	0	1 Year
Clearbridge Investments, LLC	0	One Year
FRANKLIN STRATEGIC SERIES	0	One Year
Putnam	0	One Year
Candriam S.C.A.	0	One Year
Ensign Peak Advisors, Inc	0	3 Years
DRIEHAUS CAPITAL MANAGEMENT LLC	0	One Year
Legg Mason	0	One Year

Showing the 25 largest of 250 asset managers. See all 250 in the interactive database.

3. To elect the Board's two nominees for Class II director named as nominees to hold office until the 2029 Annual Meeting of Stockholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal: Christina Rossi

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

99.8% Majority: yes · of votes cast

FOR 99.8%

FOR: 67,531,501WITHHELD: 89,825

CG Oncology, Inc.’s own tally for this item (“Elect Director: Christina Rossi”): 67,531,501 for, 89,825 withheld, per its Form 8-K filed 2026-06-08 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 88,007,761 outstanding shares: 77% for, 0.2% withheld (77% of the company cast a for/withheld vote).

The 85 asset managers below cast 100% of the shares they voted on this item FOR (28,864,787 for, 0 against).

FOR 99.9%

FOR: 28,864,787 (99.9%)ABSTAIN: 22,684 (0.1%)

Largest asset managers voting on “To elect the Board's two nominees for Class II director named as nominees to hold office until the 2029 Annual” at CG Oncology, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	9,215,536	0	For
T. Rowe Price	6,951,557	0	For
Fidelity	2,911,157	0	For
BlackRock	1,829,138	0	For
Jackson National	785,996	0	For
FRANKLIN STRATEGIC SERIES	727,381	0	For
Charles Schwab	541,958	0	For
State Street	405,333	0	For
AllianceBernstein	388,943	0	For
Legg Mason	381,329	0	For
MUTUAL FUND SERIES TRUST	366,397	0	For
First Trust	330,663	0	For
Prudential/PGIM	282,523	0	For
Equitable	251,573	0	For
AB DISCOVERY GROWTH FUND, INC.	245,891	0	For
Lord Abbett	227,058	0	For
Putnam	222,650	0	For
Hartford	205,514	0	For
PENN SERIES FUNDS INC	191,487	0	For
DRIEHAUS MUTUAL FUNDS	176,920	0	For
Goldman Sachs	161,696	0	For
John Hancock	138,297	0	For
MFS	136,863	0	For
Brighthouse	110,852	22,684	For
Federated Hermes	121,134	0	For

Showing the 25 largest of 85 asset managers. See all 85 in the interactive database.

4. To elect the Board's two nominees for Class II director named as nominees to hold office until the 2029 Annual Meeting of Stockholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal: Victor Tong, Jr.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

92% Majority: yes · of votes cast

FOR 92%8%

FOR: 62,401,874WITHHELD: 5,219,452

CG Oncology, Inc.’s own tally for this item (“Elect Director: Victor Tong, Jr.”): 62,401,874 for, 5,219,452 withheld, per its Form 8-K filed 2026-06-08 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 88,007,761 outstanding shares: 71% for, 6% withheld (77% of the company cast a for/withheld vote).

The 85 asset managers below cast 100% of the shares they voted on this item FOR (27,685,863 for, 0 against).

FOR 96%

FOR: 27,685,863 (95.8%)ABSTAIN: 1,201,608 (4.2%)

Largest asset managers voting on “To elect the Board's two nominees for Class II director named as nominees to hold office until the 2029 Annual” at CG Oncology, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	9,212,889	2,647	For
T. Rowe Price	6,951,557	0	For
Fidelity	2,911,157	0	For
BlackRock	1,829,138	0	For
Jackson National	737,524	48,472	For
FRANKLIN STRATEGIC SERIES	727,381	0	For
Charles Schwab	541,958	0	For
State Street	404,854	479	For
AllianceBernstein	388,943	0	For
Legg Mason	381,329	0	For
MUTUAL FUND SERIES TRUST	366,397	0	For
First Trust	0	330,663	Abstain
Prudential/PGIM	232,939	49,584	For
Equitable	251,573	0	For
AB DISCOVERY GROWTH FUND, INC.	245,891	0	For
Lord Abbett	227,058	0	For
Putnam	222,650	0	For
Hartford	205,514	0	For
PENN SERIES FUNDS INC	191,487	0	For
DRIEHAUS MUTUAL FUNDS	0	176,920	Abstain
Goldman Sachs	161,696	0	For
John Hancock	122,526	15,771	For
MFS	0	136,863	Abstain
Brighthouse	90,572	42,964	For
Federated Hermes	121,134	0	For

Showing the 25 largest of 85 asset managers. See all 85 in the interactive database.

5. To ratify the appointment by the Audit Committee of the Board of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.

AUDIT-RELATEDMajority of the votes cast: yes

99.9% Majority: yes · of votes cast

FOR 99.9%

FOR: 83,711,522AGAINST: 4,103

CG Oncology, Inc.’s own tally for this item (“Proposal 2: Ratification of the Selection of Independent Registered Public Accounting Firm The Company's stockholders ratified the selection by the Audit Committee of the Company's Board of Directors of Ernst & Young LLP”): 83,711,522 for, 4,103 against, per its Form 8-K filed 2026-06-08 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 88,007,761 outstanding shares: 95% for, 0.1% against (95% of the company cast a for/against vote).

The 85 asset managers below cast 100% of the shares they voted on this item FOR (28,864,787 for, 0 against).

FOR 99.9%

FOR: 28,864,787 (99.9%)ABSTAIN: 22,684 (0.1%)

Largest asset managers voting on “To ratify the appointment by the Audit Committee of the Board of Ernst & Young LLP as the Company's independen” at CG Oncology, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	9,215,536	0	For
T. Rowe Price	6,951,557	0	For
Fidelity	2,911,157	0	For
BlackRock	1,829,138	0	For
Jackson National	785,996	0	For
FRANKLIN STRATEGIC SERIES	727,381	0	For
Charles Schwab	541,958	0	For
State Street	405,333	0	For
AllianceBernstein	388,943	0	For
Legg Mason	381,329	0	For
MUTUAL FUND SERIES TRUST	366,397	0	For
First Trust	330,663	0	For
Prudential/PGIM	282,523	0	For
Equitable	251,573	0	For
AB DISCOVERY GROWTH FUND, INC.	245,891	0	For
Lord Abbett	227,058	0	For
Putnam	222,650	0	For
Hartford	205,514	0	For
PENN SERIES FUNDS INC	191,487	0	For
DRIEHAUS MUTUAL FUNDS	176,920	0	For
Goldman Sachs	161,696	0	For
John Hancock	138,297	0	For
MFS	136,863	0	For
Brighthouse	110,852	22,684	For
Federated Hermes	121,134	0	For

Showing the 25 largest of 85 asset managers. See all 85 in the interactive database.

Largest CG Oncology, Inc. shareholders voting in 2025-2026

Ranked by the number of CG Oncology, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 88,007,761 shares outstanding at the time of that meeting.

Top CG Oncology, Inc. shareholders by shares voted, 2025-2026
#	Asset manager	% of shares outstanding
1	T. Rowe Price	19.34%
2	Vanguard	11.09%
3	RTW INVESTMENTS, LP	7.97%
4	Decheng Capital LLC	7.24%
5	Fidelity	5.56%
6	Wellington	4.57%
7	BlackRock	3.69%
8	Foresite Capital Management VI LLC	2.52%
9	AllianceBernstein	1.70%
10	Avidity Partners Management LP	1.46%

Reported CG Oncology, Inc. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

CG Oncology, Inc. beneficial owners on record for the 2025-2026 proxy season
Holder	% outstanding	Disclosure
RTW Investments, LP	9.67%	13G
Vanguard Group	7.43%	13F
Decheng Capital Global Life Sciences Fund IV, L.P.	7.24%	DEF14A
Entities affiliated with Wellington Management Group LLP	6.26%	DEF14A
Wellington Management	6.10%	13F
BlackRock	5.75%	13F
Entities affiliated with Longitude Venture Partners	5.30%	DEF14A
James B. Tananbaum	4.89%	13G
FMR (Fidelity)	4.28%	13F
T. Rowe Price	4.15%	13F

Percentages above are of 88,007,761 shares outstanding, as reported by CG Oncology, Inc. on its Form 10-Q dated 2026-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from CG Oncology, Inc.’s 10-Q dated 2026-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At CG Oncology, Inc.'s shareholder meeting held 2026-06-04, in the 2025-2026 proxy season, 260 asset managers reported how they voted in their SEC Form N-PX filings, covering 2,154 separate fund positions. Their filings are grouped here into 5 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of the Company's Named Executive Officers. — FOR was 98% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: CG Oncology, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2026-06-08.

CG Oncology, Inc. proxy season coverage: 2025-2026 (this page).